| Literature DB >> 30037823 |
Hang Yang1, Jingjing Xu2, Wuyou Li2, Shujuan Wang1, Junhua Li1, Junping Yu1, Yuhong Li3, Hongping Wei4.
Abstract
New anti-infective approaches are much needed to control multi-drug-resistant (MDR) pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA). Here, we found for the first time that a recombinant protein derived from the cell wall binding domain (CBD) of the bacteriophage lysin PlyV12, designated as V12CBD, could attenuate S. aureus virulence and enhance host immune defenses via multiple manners. After binding with V12CBD, S. aureus became less invasive to epithelial cells and more susceptible to macrophage killing. The expressions of multiple important virulence genes of S. aureus were reduced 2.4- to 23.4-fold as response to V12CBD More significantly, V12CBD could activate macrophages through NF-κB pathway and enhance phagocytosis against S. aureus As a result, good protections of the mice from MRSA infections were achieved in therapeutic and prophylactic models. These unique functions of V12CBD would render it a novel alternative molecule to control MDRS. aureus infections.Entities:
Keywords: anti‐virulence therapy; bacteriophage lysin; cell wall binding domain; immune clearance; macrophage activation
Mesh:
Substances:
Year: 2018 PMID: 30037823 PMCID: PMC6120661 DOI: 10.15252/embj.201798045
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598